The purpose of this guidance is to identify the types of decision support software functionalities that: (1) do not meet the definition of a device as amended by the Cures Act; (2) may meet the definition of a device but for which FDA does not intend to enforce compliance with applicable requirements of the FD&C Act, including, but not limited to, premarket clearance and premarket approval requirements; and (3) FDA intends to focus its regulatory oversight on.
News & Trends
Procurar
Recentes
- FARMACOVIGILÂNCIA avançada: ““Excelente! Organizada e abrangente !”
- Study on the deployment of AI in healthcare Final report
- Boas Práticas de Fabrico . GMP 2025: “Formação foi muito útil a nível de aplicabilidade “
- Conducting Clinical Trials With Decentralized Elements. Guidance for Industry, Investigators, and Other Interested Parties
- COMMISSION IMPLEMENTING REGULATION (EU) 2025/2086 of 17 October 2025
- Main root causes of shortages: Analysis of reported root causes during 2022 & 2023
- EUDAMED Release note v 2.18.0
- The ICH E2D(R1) Guideline reaches Step 4 of the ICH Process

